Valuation: GH Research PLC

Market Cap 1.42B 1.28B 1.18B 1.07B 2B 135B 2.02B 14.1B 5.62B 70.85B 5.33B 5.22B 225B P/E 2026 *
-17.3x
P/E 2027 * -11.3x
Enterprise Value 1.1B 990M 915M 829M 1.55B 105B 1.57B 10.95B 4.36B 55B 4.14B 4.05B 175B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
75.54%
Yield 2026 *
-
Yield 2027 * -
1 day+3.45%
1 week+9.52%
Current month-11.80%
1 month-11.57%
3 months-25.93%
6 months+4.33%
Current year+63.07%
1 week 17.54
Extreme 17.54
20.79
1 month 17.54
Extreme 17.54
24.92
Current year 12.77
Extreme 12.77
31.44
1 year 12.04
Extreme 12.04
31.44
3 years 5.05
Extreme 5.05
31.44
5 years 5.05
Extreme 5.05
31.44
10 years 5.05
Extreme 5.05
31.44
Manager TitleAgeSince
Chief Executive Officer 51 2024-09-02
Corporate Officer/Principal 29 2020-10-31
Director of Finance/CFO 40 2020-12-31
Director TitleAgeSince
Chairman 57 2017-12-31
Director/Board Member 60 2020-11-30
Director/Board Member 61 2021-09-23
Date Insider Type Main position Quantity % Market Cap. Importance
9/8/26 Free

Founder

2,303 0.0034%
8/11/26 Free

Director

2,202 0.0032%
8/11/26 Free

Director

102,202 0.1491%
Change 5-day change 1-year change 3-year change Capi.($)
+3.45%+9.52%+47.93%+199.71% 1.37B
+0.65%-3.36%+36.98%+60.50% 63.48B
+1.76%+1.27%+11.82%+81.21% 54.55B
-0.94%+0.99%+10.45%+100.19% 53.59B
+2.76%+0.87%+27.92%+55.07% 44.75B
+2.00%-3.39%+17.83%+119.04% 41.62B
+1.34%-2.86%+224.43%+914.08% 39.91B
+0.64%-3.95%+11.15%+45.57% 32.47B
+29.06%+47.63%+107.12%+92.73% 26.7B
-0.91%+1.41%+25.48%-9.11% 23.36B
Average +3.98%+0.91%+52.11%+165.90% 38.18B
Weighted average by Cap. +2.95%+0.09%+48.15%+161.23%

Financials

2026 *2027 *
Net sales - -
Net income -80.99M -72.67M -67.18M -60.85M -114M -7.71B -115M -803M -320M -4.04B -304M -298M -12.81B -132M -119M -110M -99.26M -185M -12.58B -188M -1.31B -522M -6.58B -496M -485M -20.9B
Net Debt -318M -285M -264M -239M -446M -30.29B -452M -3.15B -1.26B -15.85B -1.19B -1.17B -50.31B -298M -268M -247M -224M -418M -28.4B -424M -2.96B -1.18B -14.86B -1.12B -1.1B -47.17B
Projected Income Statement - Annual - GH Research PLC
Logo GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company. The Company is focusing on developing its novel and proprietary mebufotenin therapies for the treatment of patients with treatment-resistant depression (TRD). Its portfolio includes GH001, its proprietary inhalable mebufotenin product candidate and GH002, its proprietary intravenous mebufotenin product candidate. GH001 is delivered via a vaporization device produced by a third party, and the Company is developing a proprietary aerosol delivery device which is in clinical investigation in Europe. GH001 completed two Phase 1 clinical trials in healthy volunteers, a Phase 1/2 trial in TRD and two Phase 2a proof-of-concept trials. GH002 Completed a randomized, double-blind, placebo-controlled, dose-ranging clinical pharmacology trial of GH002 in healthy volunteers, and it is developing GH002 within its focus area of psychiatric and neurological disorders.
Employees
73
Date Price Change Volume
26-10-28 US$20.71 +3.45% 198,760
26-10-27 US$20.02 +4.38% 299,979
26-10-26 US$19.18 +6.14% 306,079
26-10-23 US$18.07 -2.32% 699,431
26-10-22 US$18.50 -2.17% 329,178
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - GH Research PLC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
20.71USD
Average target price
42.89USD
Spread / Average Target
+107.09%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - GH Research PLC
  1. Stock Market
  2. Stocks
  3. GHRS Stock